Clene Announces $7 Million Underwritten Offering of Common Stock
Rhea-AI Summary
Clene (Nasdaq: CLNN)/b) priced an underwritten registered direct offering of at $7.00 per share, for gross proceeds of approximately $7.0 million. The offering is expected to close on or about May 6, 2026, subject to customary closing conditions.
Proceeds are expected to fund NDA preparation for CNM-Au8, continued access and a future confirmatory Phase 3 trial, manufacturing expansion, potential commercialization efforts, and early-stage R&D. Canaccord Genuity is sole bookrunner; the offering is made under an effective Form S-3 shelf registration.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- $7.0M gross proceeds from offering
- Issuance of 1,000,000 shares provides immediate cash runway
- Proceeds earmarked to fund NDA preparation for CNM-Au8
- Proceeds support a future confirmatory Phase 3 clinical trial
Negative
- Issuance of 1,000,000 shares will dilute existing shareholders
- Underwriting discounts and offering expenses will reduce net proceeds
- Capital raise indicates need for external funding before commercialization
News Market Reaction – CLNN
On the day this news was published, CLNN declined 18.67%, reflecting a significant negative market reaction. Argus tracked a peak move of +2.6% during that session. Argus tracked a trough of -10.4% from its starting point during tracking. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $22M from the company's valuation, bringing the market cap to $95.29M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 09 | Registered direct offering | Negative | +7.1% | Announced ~$28M registered direct with warrant-linked tranches for CNM-Au8 funding. |
| Oct 01 | Financing and debt amend | Negative | +6.3% | $7.3M registered direct plus private placements and debt facility amendment to extend runway. |
| Sep 30 | Offering announcement | Negative | -4.8% | $7.3M registered direct and concurrent private placements priced at market with warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past equity offerings often saw price strength, with two prior events posting positive next-day moves despite dilutive implications.
Recent financing history shows Clene repeatedly using equity offerings to fund CNM-Au8. A $7.3M registered direct and private placements in Sep–Oct 2024 and a larger registered direct of about $28M in Jan 2026 supported operations and regulatory work. Those prior offerings were linked to ALS development and accelerated-approval plans. Today’s underwritten offering similarly channels capital toward the planned NDA for CNM-Au8, ongoing access programs, a future Phase 3 trial, and potential commercialization.
Historical Comparison
Past offering-related headlines (3 events, average move 2.88%) often coincided with resilience or gains, suggesting Clene’s capital raises have not always pressured shares.
Financings since 2024 have repeatedly funded CNM-Au8’s clinical development, regulatory steps toward an ALS NDA, and preparation for potential commercialization.
Regulatory & Risk Context
An effective Form S-3 shelf dated Sep 5, 2025 covers resale of up to 491,496 shares tied to convertible notes. Clene receives no proceeds from these resales, having already raised cash via the underlying notes, while the prospectus highlights recurring losses and substantial doubt about its ability to continue as a going concern.
Key Terms
underwritten registered direct offering financial
new drug application (nda) regulatory
phase 3 clinical trial medical
bookrunner financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
prospectus regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced the pricing of an underwritten registered direct offering of 1,000,000 shares of common stock at a purchase price of
The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately
The offering is expected to close on or about May 6, 2026, subject to the satisfaction of customary closing conditions.
Canaccord Genuity LLC is acting as sole bookrunner for the offering.
The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-286058), previously filed with the Securities and Exchange Commission (SEC) under the Securities Act of 1933, as amended. The offering is being made only by means of a prospectus and a prospectus supplement which forms a part of the effective registration statement relating to the offering. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC's website at www.sec.gov and may also be obtained, when available, by contacting Canaccord Genuity LLC, Attn: Syndication Department, 1 Post Office Square, 30th Floor, Boston, MA 02109, or by email at prospectus@cgf.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the shares of common stock. Clene will not, and has been advised by the underwriter that it and its affiliates will not, sell any of the shares of common stock in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Clene
Clene Inc. (Nasdaq: CLNN), along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
About CNM-Au8®
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Clene’s forward-looking statements include, but are not limited to, statements regarding the amount of the gross proceeds, and the timing of the closing of the offering. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
Investor Contact: Kevin Gardner, LifeSci Advisors; kgardner@lifesciadvisors.com; 617-283-2856
Media Contact: Caroline Wagner, Forbes Tate Partners; CWagner@forbes-tate.com; (267) 294-6563
